News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
14,025 Results
Type
Article (785)
Company Profile (19)
Press Release (13221)
Section
Business (4612)
Career Advice (16)
Deals (671)
Drug Delivery (2)
Drug Development (2516)
Employer Resources (2)
FDA (297)
Job Trends (340)
News (7639)
Policy (420)
Tag
2024 Bio NC Standard (1)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (1)
2024 Pharm Country Standard (1)
Academia (38)
Adcomms (3)
Allergies (4)
Alliances (1239)
ALS (1)
Alzheimer's disease (10)
Antibody-drug conjugate (ADC) (8)
Approvals (294)
Artificial intelligence (5)
Bankruptcy (6)
Best Places to Work (289)
BIOSECURE Act (4)
Biosimilars (1)
Biotechnology (15)
Cancer (55)
Cardiovascular disease (6)
Career advice (10)
CAR-T (9)
Cell therapy (27)
Clinical research (1952)
Collaboration (32)
Compensation (14)
COVID-19 (104)
CRISPR (4)
C-suite (9)
Cystic fibrosis (1)
Data (57)
Diabetes (3)
Diagnostics (37)
Drug discovery (1)
Earnings (1469)
Editorial (1)
Employer resources (2)
Events (2534)
Executive appointments (31)
FDA (326)
Featured Employer (2)
Funding (29)
Gene editing (8)
Gene therapy (17)
GLP-1 (21)
Government (50)
Guidances (1)
Healthcare (402)
Immunology and inflammation (2)
Indications (1)
Infectious disease (105)
Inflammatory bowel disease (7)
Intellectual property (3)
Interviews (3)
IPO (368)
Job creations (61)
Job search strategy (10)
Kidney cancer (1)
Labor market (2)
Layoffs (12)
Legal (69)
Liver cancer (1)
Lung cancer (6)
Lymphoma (10)
Management (1)
Manufacturing (8)
Medical device (124)
Medtech (124)
Mergers & acquisitions (318)
Metabolic disorders (6)
Neurodegenerative disease (4)
Neuroscience (17)
NextGen: Class of 2025 (149)
Non-profit (21)
Northern California (107)
Now hiring (1)
Obesity (3)
Opinion (1)
Ovarian cancer (1)
Pain (7)
Pancreatic cancer (1)
Parkinson's disease (2)
Patents (12)
Patient recruitment (3)
People (1712)
Phase I (820)
Phase II (901)
Phase III (664)
Pipeline (29)
Policy (6)
Postmarket research (33)
Preclinical (275)
Press Release (2)
Prostate cancer (2)
Radiopharmaceuticals (2)
Rare diseases (7)
Real estate (112)
Recruiting (1)
Regulatory (350)
Reports (2)
Research institute (63)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (10)
Series B (3)
Service/supplier (1)
Southern California (94)
Special edition (1)
Spinal muscular atrophy (1)
Sponsored (1)
Startups (107)
Supply chain (1)
United States (650)
Vaccines (11)
Webinars (1)
Weight loss (1)
Date
Today (3)
Last 7 days (22)
Last 30 days (81)
Last 365 days (1090)
2025 (255)
2024 (1123)
2023 (1347)
2022 (1722)
2021 (1734)
2020 (1332)
2019 (810)
2018 (595)
2017 (728)
2016 (578)
2015 (628)
2014 (431)
2013 (367)
2012 (320)
2011 (322)
2010 (328)
Location
Africa (14)
Asia (1101)
Australia (91)
California (275)
Canada (75)
China (20)
Colorado (2)
Connecticut (7)
Delaware (5)
Europe (1454)
Florida (18)
Georgia (7)
Idaho (1)
Illinois (9)
India (1)
Indiana (2)
Japan (2)
Maine (1)
Maryland (46)
Massachusetts (116)
Michigan (1)
Minnesota (4)
New Jersey (49)
New Mexico (1)
New York (23)
North Carolina (14)
Northern California (107)
Ohio (2)
Oklahoma (1)
Pennsylvania (44)
South America (9)
Southern California (94)
Tennessee (1)
Texas (19)
Utah (3)
Washington D.C. (2)
Washington State (9)
Wisconsin (1)
14,025 Results for "axial biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
BioMidwest
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
UCB announced the first presentation of two-year data from the Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension, BE MOVING, evaluating BIMZELX, an interleukin -17A and IL-17F inhibitor, in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis, also known as radiographic axial spondyloarthritis.
June 12, 2024
·
21 min read
Press Releases
Augurex to Present Axial Spondyloarthritis Data and Exhibit at ACR Convergence 2024 in Washington, DC
November 7, 2024
·
3 min read
Genetown
Axial Therapeutics to Present at Upcoming Conferences - Jan 05, 2024
Axial Therapeutics announced that A. Stewart Campbell, PhD, Chief Executive Officer, will participate in the following upcoming conferences.
January 5, 2024
·
1 min read
Press Releases
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
November 14, 2024
·
24 min read
Press Releases
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
·
3 min read
Press Releases
Augurex and New Day Diagnostics Announce Launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents; Enabling a First-In-Class Diagnostic Test for Axial Spondyloarthritis
November 13, 2024
·
4 min read
FDA
Axial3D Receives FDA Clearance for Axial3D INSIGHT™ Medical Image Segmentation Platform
Axial3D today announced that it is the first to receive FDA clearance for an automated, AI-driven, cloud-based segmentation platform for orthopedic trauma, orthopedic, maxillofacial, and cardiovascular applications.
July 31, 2023
·
4 min read
Press Releases
UCB and University Health Network (UHN) Collaborate to Enhance Axial Spondyloarthritis (axSpA) Care in Canada
August 2, 2024
·
4 min read
Press Releases
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
April 2, 2025
·
1 min read
1 of 1,403
Next
